Article citationsMore>>

Inukai, K., Watanabe, M., Nakashima, Y., Sawa, T., Takata, N., Tanaka, M., Kashiwabara, H., Yokota, K., Suzuki, M., Kurihara, S., Awata, T. and Katayama, S. (2005) Efficacy of glimepiride in Japanese Type 2 diabetic subjects. Diabetes Research and Clinical Practice, 68, 250-257. http://dx.doi.org/10. 1016/j.diabres.2004.10.002

has been cited by the following article:

• TITLE: Effects of long-term monotherapy with glimepiride vs glibenclamide on glycemic control and macrovascular events in Japanese Type 2 diabetic patients

  AUTHORS: Hirohisa Onuma, Kouichi Inukai, Masaki Watanabe, Yoshikazu Sumitani, Toshio Hosaka, Hitoshi Ishida

  KEYWORDS: Glibenclamide; Glimepiride; Macrovascular Events; HOMA-R/β

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.4 No.1, January 20, 2014

  ABSTRACT: We investigated whether long-term glimepiride (GP) monotherapy improves insulin resistance and exerts a beneficial effect on beta cell function, as compared with glibenclamide (GC). One hundred Japanese Type 2 diabetic patients were randomly assigned to the GP (n = 50) or the GC (n = 50) group. During a 5-year monitoring period, patients received the indicated SU monotherapy, while changes in SU doses were allowed as needed to maintain HbA1C below 7.0%. The GC group, in parallel with fasting insulin, showed a rapid homeostatic model assessment (HOMA)-R increase and maintained a high HOMA-R level. In contrast, HOMA-R in the GP group decreased continuously, from 2.9 at baseline to 1.8 at study completion. In the GC group, HOMA-b was markedly increased in the first 6 months, then gradually decreased through 18 months. While the HOMA-β elevation in the GP group was more moderate than that in the GC group, HOMA-β levels were maintained with a slight decrease. The cumulative macrovascular disease outcome was 1 for the GP and 7 for the GC group, showing a significant difference. These results suggest that glimepiride monotherapy markedly improved HOMA-R with moderate insulin stimulation, which may account for the difference in macrovascular disease development as compared with the group receiving glibenclamide.